BioWraptor raises $1.5 million to advance room-temperature biologics stabilization

BioWraptor closed a $1.5 million pre-seed round to scale technology that stabilizes fragile biomolecules without refrigeration. The New York biotech says the funding will help accelerate customer pilots and commercialization for healthcare products that depend on cold-chain logistics.

Why it matters: - BioWraptor is targeting one of biomedicine's biggest distribution problems: keeping sensitive products cold from manufacturing to end use. - Room-temperature stabilization could reduce refrigeration costs, energy use and emissions across healthcare supply chains. - The technology could also widen access to vaccines, diagnostics, medicines and other biologics in places with limited cold storage.

What happened: - BioWraptor closed a $1.5 million pre-seed round. - The company said the funding will support expanded laboratory resourcing and capabilities. - BioWraptor plans to use the capital to speed customer pilots and product commercialization in life sciences. - Investors in the round included Anima x Alpha Star, SNOCAP, NY Ventures, and angels Pascal and Bérangère Marguet, Ryan Jeffery, and Dolgin and Greg Haar.

The details: - BioWraptor develops naturally derived building blocks that form a protective wrap around fragile biomolecules. - The platform stabilizes biomolecules at room temperature. - The approach is inspired by tardigrades, microscopic organisms known for surviving extreme environmental conditions. - The company says its technology could reduce or potentially eliminate refrigeration in applicable healthcare products. - BioWraptor says that shift could simplify distribution and lower energy use and related emissions. - The platform also has potential applications in agriculture, cosmetics, space and other biotechnology areas. - BioWraptor's approach builds on research into biomolecular stabilization, including work published by Maëva Coste and a City University of New York scientific team in Nature Materials. - BioWraptor was founded by Maëva Coste and Jen Laws. - The company participates in Activate, NYCEDC Newlab Founder Fellows, Communitas America Accelerator, NY Innovation Hot Spot, The Life Science Entrepreneurship program, Materialize accelerator, Ray of Hope Accelerator and BioTools Innovator. - BioWraptor was named a 2026 nominee for the Prix Galien USA EcoHealth Award. - The award recognizes innovations that advance human health while protecting the environment.

Between the lines: - The investor mix suggests interest in both scientific novelty and commercialization potential. - BioWraptor is positioning the product as a logistics and sustainability play, not just a lab materials innovation. - The company is leaning on a nature-inspired narrative that could appeal to healthcare, industrial and consumer biotech markets. - CEO Maëva Coste said the goal is to make healthcare distribution more accessible, resilient and sustainable by reducing reliance on refrigeration. - Jonathan Azoff, co-founder and general partner at SNOCAP, said the innovation could lower costs for essentials from groceries to pharmaceuticals while reducing energy demand across supply chains. - Sandra Rey, CEO of Anima, said BioWraptor combines strong science, a nature-based strategy and founders suited to the mission.

What's next: - BioWraptor will use the new funding to expand lab work and move more customer pilots toward commercialization. - The company will likely continue building evidence for performance across healthcare and other biotech use cases. - BioWraptor is also likely to keep advancing industry visibility through accelerator programs and award recognition.

The bottom line: - BioWraptor is betting that biomolecules can be protected at room temperature, cutting cold-chain dependence and opening new commercial uses for biologics.